Acid Sphingomyelinase Deficiency (ASMD) Market ANALYSE DE LA TAILLE ET DU PARTAGE - TENDANCES DE CROISSANCE ET PRÉVISIONS (2024 - 2031)
Acid Sphingomyelinase Deficiency (ASMD) Market is segmented By Therapy (XENPOZYME (olipudase alfa), Other Enzyme Replacement Therapies (ERT)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned segments.
Acid Sphingomyelinase Deficiency (ASMD) Market Size
Taille du Marché en USD Mn
TCAC12.1%
| Période d'Étude | 2024 - 2031 |
| Année de Base de l'Estimation | 2023 |
| TCAC | 12.1% |
| Concentration du Marché | High |
| Principaux Acteurs | Sanofi, Orphazyme, Takeda Pharmaceutical, Actelion Pharmaceuticals and Among Others. |
*Avertissement : Les principaux acteurs sont listés sans ordre particulier.
*Source : Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
Acid Sphingomyelinase Deficiency (ASMD) Market Analysis
The acid sphingomyelinase deficiency (ASMD) market is estimated to be valued at USD 134.6 Mn in 2024 and is expected to reach USD 300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031. The market is expected to showcase significant growth during the forecast period due to the rising diagnosis of ASMD and growing access to enzyme replacement therapies.